Smallpox Disease and Smallpox Vaccine information paper (includes updated guidance on avoiding contamination while drawing vaccine from the vial)
Questions and Answers about Smallpox and Smallpox Vaccine
Smallpox disease had a mortality rate of approximately 30 percent, and because of a successful vaccination program it was declared globally eradicated in 1980. Naturally occurring smallpox was highly contagious, and was transmitted from an infected person to a susceptible (unvaccinated) person by close contact with respiratory secretions and/or infected skin. When smallpox disease was circulating, the only known reservoir for the virus was humans.
Once infected, a person usually has no symptoms and is not contagious during the incubation period, which ranges from 7-17 days. Symptoms then begin with high fever, headache, body aches and fatigue. This may last 2-4 days, and then the rash develops. The rash first appears on the oral mucosa, face, and forearms, then spreads to the trunk and legs. A person is most infectious during the first week of the rash and is no longer infectious after all scabs have separated, usually 3-4 weeks after onset.
There is currently one smallpox vaccine licensed in the United States, ACAM2000, and is given in a pre-event setting only to select, designated groups including certain members of the U.S. military. The smallpox vaccine is administered in a single dose by the percutaneous route (scarification) using 15 jabs with a stainless steel bifurcated needle that has been dipped into the reconstituted vaccine. A few days following successful administration of the vaccine, a lesion forms at the vaccination site. This lesion contains vaccinia virus capable of infecting other parts of your body or infecting others who come in contact with the vaccination site directly or anything that contains drainage from the lesion. For this reason, all smallpox vaccinees are taught, and must practice, proper vaccination site and dressing care.
Source: Centers for Disease Control and Prevention
You also may be interested in...
Policy
Jun 4, 2018
.PDF |
222.04 KB
Mandatory administration of anthrax and smallpox vaccines for requirements not listed in existing guidance must be authorized by an approved Exception to Policy (ETP).
- Identification #: N/A
- Type: Memorandums
Policy
Nov 12, 2015
.PDF |
1.77 MB
Clarifying Guidance for Smallpox and Anthrax Vaccine Immunization Programs
- Identification #: N/A
- Type: Guidelines
Policy
Oct 30, 2008
.PDF |
92.81 KB
MEDCOM Participation in ACAM2000 Smallpox Vaccine Post-Licensure Safety Surveillance and Research Requirements
- Identification #: N/A
- Type: Directives
Policy
Sep 23, 2008
.PDF |
11.29 KB
BUMED UPDATE TO CLINICAL POLICY FOR DOD SMALLPOX VACCINATION
- Identification #: N/A
- Type: Directives
Policy
Apr 15, 2008
.PDF |
132.91 KB
Department of Defense Participation in ACAM2000 Smallpox Vaccine Post Marketing Research Requirements
- Identification #: N/A
- Type: Directives
Policy
Apr 1, 2008
.PDF |
2.13 MB
Update to Clinical Policy for the Department of Defense Smallpox Vaccination Program
- Identification #: 08-004
- Type: Memorandums
Policy
Mar 3, 2008
.PDF |
194.62 KB
Coast Guard Smallpox Vaccine Program
- Identification #: N/A
- Type: Directives
Policy
Feb 27, 2008
.PDF |
15.92 KB
ALNAV TRANSITION FROM CURRENT DRYVAX SMALLPOX VACCINE TO ACAM2000 SMALLPOX VACCINE
- Identification #: N/A
- Type: Directives
Policy
Feb 14, 2008
.PDF |
16.54 KB
ALARACT DOD'S TRANSITION TO ACAM2000 BRAND OF SMALLPOX VACCINE
- Identification #: N/A
- Type: Directives
Policy
Jan 31, 2008
.PDF |
475.01 KB
Transition to ACAM2000 Smallpox Vaccine
- Identification #: N/A
- Type: Directives
Policy
Mar 30, 2007
.PDF |
2.79 MB
Smallpox Immunization Program Safety - Remain Vigilant
- Identification #: N/A
- Type: Directives
Policy
Aug 22, 2005
.PDF |
217.00 KB
DoD Immunization Program for Biological Warfare Defense AFEB 2005-06
- Identification #: N/A
- Type: Memorandums
Policy
Dec 21, 2004
.PDF |
70.23 KB
ALMAJCOM SMALLPOX VACCINATIONS FOR CIVILIANS AND CONTRACTORS IN NEWLY DESIGNATED AREAS
- Identification #: N/A
- Type: Directives
Policy
Dec 21, 2004
.PDF |
56.42 KB
MARADMIN EXPANSION OF SMALLPOX IMMUNIZATION PROGRAM AND AUTHORIZATION TO BEGIN IMMUNIZATIONS 60 DAYS PRIOR TO DEPLOYMENT
- Identification #: N/A
- Type: Directives
Policy
Jan 5, 2004
.PDF |
62.91 KB
MARADMIN SMALLPOX VACCINATIONS AND REPORTING FOR OIF II
- Identification #: N/A
- Type: Directives
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: July 11, 2023